Trump Announces Plan to Expand Medicare Coverage for GLP-1s, Aligning With MFN Pricing

WASHINGTON, DC — November 6, 2025 — Speaking from the Oval Office, President Donald J. Trump unveiled a sweeping new plan aimed at lowering prescription drug costs and expanding coverage for millions of Americans. The initiative includes landmark agreements with Eli Lilly and Company and Novo Nordisk to dramatically reduce prices on some of the nation’s most widely used medications, including Ozempic, Wegovy, and Zepbound, with a stronger effort to align with most-favored-nation pricing.

The announcement marks what the administration called “the latest in a series of the most significant actions ever taken by our Federal government to lower prescription drug prices.”

Lower Prices for Obesity and Chronic Disease Drugs

The deal targets drugs with the highest annual expenditures in the United States — medications used to treat obesity, diabetes, and related chronic conditions. Under the new agreement, the prices of Ozempic and Wegovy, “slashing cost of Wegovy to $1350 a month to ultimately $250 a month,” President Trump said in his address from the Oval Office.

The price of Zepbound and Orforglipron (pending FDA approval) will be reduced from $1086 to an average of $346 per month under the same program. Future oral GLP-1 therapies, if approved, will launch at $150 per month through TrumpRx.

Expanded Coverage for Medicare and Medicaid

The Centers for Medicare & Medicaid Services (CMS) will begin covering Wegovy and Zepbound for adults with obesity and related comorbidities—the first time these drugs will be covered under federal programs.

Medicare beneficiaries will pay a $50 monthly copay, and Medicaid programs in all 50 states will gain access to the same negotiated prices. The administration said the new rates will save taxpayers billions compared to pricing frameworks proposed under the previous administration.

Medicare’s official prices for Ozempic, Wegovy, Mounjaro, and Zepbound will be $245 per month—less than half what prices were previously. The agreement also provides lower prices for other commonly prescribed medications:

• Eli Lilly’s Emgality (migraine treatment): $299 per pen (a $443 discount)
• Eli Lilly’s Trulicity (diabetes): $389 per month (a $598 discount)
• Novo Nordisk’s NovoLog and Tresiba (insulin products): $35 per month of supply

Both companies will also guarantee MFN pricing on new medicines, repatriate foreign revenue on existing products, and extend MFN pricing to all state Medicaid programs.

According to President Trump, “In case after case, our citizens pay massively higher prices than other nations pay for the same exact pill, from the same factory, effectively subsidizing socialism abroad with skyrocketing prices at home. So we would spend tremendous amounts of money in order to provide inexpensive drugs to another country. And when I say the price is different, you can see some examples where the price is beyond anything — four times, five times different.”

Key Takeaways

• Historic price reductions: Ozempic and Wegovy to drop from $1,000–$1,350 to $350 per month through TrumpRx.
• Medicare expansion: Coverage for Wegovy and Zepbound for obesity begins next year; $50 monthly copay for beneficiaries.
• TrumpRx program: Direct-to-consumer platform offering discounted prices for uninsured patients; oral GLP-1 drugs capped at $150/month. • Broader impact: Medicaid and Medicare to access Most-Favored-Nation (MFN) pricing, cutting federal drug expenditures.
• Domestic manufacturing boom: Novo Nordisk investing $10B; Eli Lilly investing $27B in US-based facilities.
• Global pricing reform: US to align drug costs with peer nations, addressing disparities in international pharmaceutical pricing.
• Public health implications: Expanded access to GLP-1 drugs expected to improve outcomes for obesity, diabetes, and cardiovascular disease.

Reference

President Donald J Trump. Fact sheet: President Donald J. Trump announces major developments in bringing most-favored-nation pricing to American patients. Whitehouse.gov. Published November 6, 2025. Accessed November 6, 2025.